Novel pharmacological targets for the treatment of Parkinson's disease

被引：0

作者：

Anthony H. V. Schapira

Erwan Bezard

Jonathan Brotchie

Frédéric Calon

Graham L. Collingridge

Borris Ferger

Bastian Hengerer

Etienne Hirsch

Peter Jenner

Nicolas Le Novère

José A. Obeso

Michael A. Schwarzschild

Umberto Spampinato

Giora Davidai

机构：

[1] Royal Free and University College Medical School,University Department of Clinical Neurosciences

[2] University College London,Department of Neurology and Neuroscience Centre

[3] Institute of Neurology,Department of Neurology

[4] Queen Square,Department of Cardiovascular Medicine and Neurology

[5] University College London,undefined

[6] CNRS UMR 5543,undefined

[7] Universite Victor Segalen–Bordeaux 2,undefined

[8] 146,undefined

[9] rue Leo Saignat,undefined

[10] Toronto Western Research Institute,undefined

[11] Toronto Western Hospital,undefined

[12] 399 Bathurst,undefined

[13] MC 11-419,undefined

[14] Molecular Endocrinology and Oncology Research Centre,undefined

[15] Centre Hospitalier de l'Université Laval Research Centre (CHUL),undefined

[16] Quebec (QC),undefined

[17] Canada,undefined

[18] G1V 4G2 and Faculty of Pharmacy,undefined

[19] Laval University,undefined

[20] MRC Centre for Synaptic Plasticity,undefined

[21] University of Bristol,undefined

[22] University Walk,undefined

[23] Boehringer Ingelheim Pharma GmbH & Co. KG,undefined

[24] INSERM,undefined

[25] UMR 679,undefined

[26] Neurology and Experimental Therapeutics,undefined

[27] University Pierre et Marie Curie,undefined

[28] Hôpital de la Pitié-Salpétrière,undefined

[29] Neurodegenerative Disease Research Centre,undefined

[30] School of Health and Biomedical Sciences,undefined

[31] King' s College,undefined

[32] Computational Neurobiology,undefined

[33] EMBL-EBI. Wellcome-Trust Genome Campus,undefined

[34] Clinica Universitaria and Medical School,undefined

[35] Universidad de Navarra and CIMA,undefined

[36] Avenida de Pio XII,undefined

[37] Massachusetts General Hospital,undefined

[38] MassGeneral Institute for Neurodegenerative Disease,undefined

[39] 14 Unité Mixte de Recherche-Centre National de la Recherche Scientifique,undefined

[40] (UMR-CNRS) 5541,undefined

[41] Université Victor Segalen Bordeaux 2,undefined

[42] 146 rue Léo Saignât,undefined

[43] B.P. 31,undefined

[44] Clinical and Scientific Affairs,undefined

[45] Boehringer Ingelheim,undefined

来源：

Nature Reviews Drug Discovery | 2006年 / 5卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Parkinson's disease is a neurodegenerative disease that results from a loss of nigrostriatal dopaminergic neurons. Clinical features include bradykinesia, rigidity and tremor. The accompanying loss of non-adrenergic, serotoninergic and cholinergic neurons leads to the progression of 'non-motor' features.Although dopamine-replacement therapies have been highly successful in improving some of the motor features of the disease, their value is limited by the development of other motor complications. Therefore there is a need for novel therapeutics, both for Parkinson's disease, and also for the motor complications that arise from the use of existing drugs.The multiplicity of dopamine receptors in the brain offers a range of potential targets, but exploitation of drugs acting on specific receptor sub-types has been disappointing. 5-hydroxytryptamine (5-HT) receptor modulators — in particular those acting at 5-HT1A, 5-HT1B, 5-HT2A and 5-HT2C receptors — could be useful, particularly with respect to levodopa-induced dyskinesia.Since the vast majority of pathways in the basal ganglia utilize glutamate and γ-amino butyric acid, these systems are obvious drug candidates, but targeting these receptor systems is fraughtwith potential complications. Recognition of the enhanced opioid peptide transmission in Parkinson's disease patients with levodopa-induced motor complications has raised the possibility of controlling these by targeting opioid transmission in the basal ganglia.Central adenosine A2A receptors are relatively selectively expressed in the striatum, which is innervated by the dopaminergic nigrostriatal neurons lost in Parkinson's disease. Therefore, its antagonism has emerged as a leading candidate strategy for the improved treatment of Parkinson's disease.Although no drug has yet been shown to be neuroprotective in Parkinson's disease, several including dopamine agonists and monoamine oxidase type B inhibitors, have been tested in clinical trials.

引用

页码：845 / 854

页数：9

共 193 条

[1] Braak H(2003)Staging of brain pathology related to sporadic Parkinson's disease Neurobiol. Aging 24 197-211
[2] Rascol O(2000)A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group N. Engl. J. Med. 34 1484-1491
[3] Holloway RG(2004)Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial Arch. Neurol. 61 1044-1053
[4] Katzenschlager R(2005)Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges Mov. Disord. 20 151-157
[5] Poewe W(2005)Clinical studies with transdermal rotigotine in early Parkinson's disease Neurology 65 S11-S14
[6] Luessi F(2002)Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and α(1)/α(2)-adrenoceptor J. Pharmacol. Exp. Ther. 303 805-814
[7] Newman-Tancredi A(2005)Does levodopa slow or hasten the rate of progression of Parkinson's disease? J. Neurol. 252 iv37-iv42
[8] Fahn S(2000)Continuous dopamine-receptor stimulation in early Parkinson's disease Trends Neurosci. 23 S117-S126
[9] Olanow W(2000)Dopamine-receptor stimulation: biobehavioral and biochemical consequences Trends Neurosci. 23 S92-S100
[10] Schapira AH(2003)Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study J. Neurol. Neurosurg. Psychiatry 74 1071-1079

← 1 2 3 4 5 6 7 8 9 10 →